Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 19, 1-11, 2017 | 133 | 2017 |
Ankylosing spondylitis: an update V Golder, L Schachna Australian family physician 42 (11), 780-784, 2013 | 131 | 2013 |
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study V Golder, R Kandane-Rathnayake, M Huq, HT Nim, W Louthrenoo, ... The Lancet Rheumatology 1 (2), e95-e102, 2019 | 92 | 2019 |
Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic V Golder, K Connelly, M Staples, E Morand, A Hoi Lupus 22 (13), 1425-1430, 2013 | 77 | 2013 |
Discordance of patient and physician health status concerns in systemic lupus erythematosus V Golder, JJY Ooi, AS Antony, T Ko, S Morton, R Kandane-Rathnayake, ... Lupus 27 (3), 501-506, 2018 | 72 | 2018 |
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus S Oon, M Huq, V Golder, PX Ong, EF Morand, M Nikpour Annals of the Rheumatic Diseases 78 (5), 629-633, 2019 | 61 | 2019 |
Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 18, 1-9, 2016 | 56 | 2016 |
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study D Apostolopoulos, R Kandane-Rathnayake, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 2 (1), e24-e30, 2020 | 54 | 2020 |
Systemic lupus erythematosus: an update. V Golder, A Hoi The Medical Journal of Australia 206 (5), 215-220, 2017 | 48 | 2017 |
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study V Golder, R Kandane-Rathnayake, M Huq, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 1 (2), e103-e110, 2019 | 47 | 2019 |
Treatment targets in SLE: remission and low disease activity state V Golder, MWP Tsang-A-Sjoe Rheumatology 59 (Supplement_5), v19-v28, 2020 | 44 | 2020 |
Development of the Asia Pacific lupus collaboration cohort R Kandane‐Rathnayake, V Golder, W Louthrenoo, SF Luo, YJ Jan Wu, ... International journal of rheumatic diseases 22 (3), 425-433, 2019 | 32 | 2019 |
Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus AL Yeo, R Koelmeyer, R Kandane‐Rathnayake, V Golder, A Hoi, M Huq, ... Arthritis Care & Research 72 (9), 1289-1295, 2020 | 28 | 2020 |
Autonomic cardiovascular control in hypotensive critically ill preterm infants is impaired during the first days of life V Golder, M Hepponstall, SR Yiallourou, A Odoi, RSC Horne Early human development 89 (6), 419-423, 2013 | 28 | 2013 |
‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study R Kandane-Rathnayake, W Louthrenoo, A Hoi, SF Luo, YJJ Wu, YH Chen, ... Arthritis Research & Therapy 24 (1), 70, 2022 | 24 | 2022 |
Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study V Golder, M Huq, K Franklyn, A Calderone, A Lateef, CS Lau, ALH Lee, ... Seminars in arthritis and rheumatism 46 (6), 798-803, 2017 | 21 | 2017 |
Disseminated enteroviral infection associated with obinutuzumab C Dendle, M Gilbertson, TM Korman, V Golder, E Morand, S Opat Emerging Infectious Diseases 21 (9), 1661, 2015 | 21 | 2015 |
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus EF Morand, G Abreu, RA Furie, V Golder, R Tummala Annals of the Rheumatic Diseases 82 (5), 639-645, 2023 | 19 | 2023 |
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study R Kandane-Rathnayake, V Golder, W Louthrenoo, YH Chen, J Cho, ... The Lancet Rheumatology 4 (12), e822-e830, 2022 | 19 | 2022 |
Clinician-reported outcome measures in lupus trials: a problem worth solving K Connelly, V Golder, R Kandane-Rathnayake, EF Morand The Lancet Rheumatology 3 (8), e595-e603, 2021 | 17 | 2021 |